Avanza Fonder AB Invests $75,000 in Autolus Therapeutics plc (NASDAQ:AUTL)

Avanza Fonder AB acquired a new stake in Autolus Therapeutics plc (NASDAQ:AUTL) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 31,770 shares of the company’s stock, valued at approximately $75,000.

Several other hedge funds and other institutional investors have also made changes to their positions in AUTL. ProShare Advisors LLC acquired a new stake in Autolus Therapeutics in the 2nd quarter valued at about $43,000. Capstone Investment Advisors LLC bought a new stake in Autolus Therapeutics in the third quarter valued at approximately $51,000. Herbst Group LLC acquired a new stake in shares of Autolus Therapeutics in the third quarter valued at approximately $91,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Autolus Therapeutics by 63.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 38,393 shares of the company’s stock worth $139,000 after acquiring an additional 14,959 shares during the period. Finally, Bellevue Group AG increased its holdings in shares of Autolus Therapeutics by 27.7% during the 3rd quarter. Bellevue Group AG now owns 41,500 shares of the company’s stock worth $151,000 after acquiring an additional 9,000 shares during the last quarter. 72.83% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on AUTL shares. Redburn Atlantic raised shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price objective for the company in a research report on Friday, November 15th. Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 target price on shares of Autolus Therapeutics in a report on Monday, January 13th. Finally, The Goldman Sachs Group raised shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and increased their price target for the company from $7.00 to $7.60 in a report on Monday, November 18th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $10.40.

Autolus Therapeutics Stock Performance

Shares of NASDAQ:AUTL opened at $2.22 on Tuesday. Autolus Therapeutics plc has a 52 week low of $2.07 and a 52 week high of $7.37. The firm has a market cap of $590.72 million, a PE ratio of -1.83 and a beta of 2.05. The firm’s fifty day moving average is $2.67 and its 200-day moving average is $3.55.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same period in the prior year, the business posted ($0.26) EPS. Sell-side analysts forecast that Autolus Therapeutics plc will post -0.94 EPS for the current year.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.